---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-030466"
form_type: "8-K"
ticker: "ADTX"
cik: "0001726711"
company_name: "Aditxt, Inc."
filed_at: "2024-04-04T23:59:59+00:00"
generated_at: "2026-06-04T02:22:06.648609+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aditxt signs agreement to acquire Appili Therapeutics for $5.7M cash plus stock

## Summary
- Acquisition for ~$5.7M cash plus ~332,876 Aditxt shares; ~$0.0467/sh + 0.002745 ADTX share per Appili share.
- Assets include FDA-approved LIKMEZ, DoD-funded ATI-1701 tularemia vaccine ($14M award), and ATI-1801 topical leishmaniasis treatment.
- Closing conditioned on Aditxt raising at least $20M financing by June 30, 2024; termination fee of CDN$1.25M if not met.
- Transaction requires Appili shareholder vote, court approval, and NASDAQ listing of Consideration Shares.
- Outstanding Appili options/warrants cashed out for additional ~$341,000 aggregate.

## SEC filing metadata
- accession: 0001213900-24-030466
- form_type: 8-K
- ticker: ADTX
- cik: 0001726711
- company_name: Aditxt, Inc.
- filed_at: 2024-04-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726711/000121390024030466/0001213900-24-030466-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726711/000121390024030466/ea0203328-8k_aditxtinc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-030466
- JSON: https://secwatch.observer/filing/0001213900-24-030466.json
- Plain text: https://secwatch.observer/filing/0001213900-24-030466.txt

## Key facts
- Material Agreements
  Aditxt, Inc. entered into Arrangement Agreement with Appili Therapeutics, Inc. (effective 2024-04-01).
  - Action: entry
  - Agreement: merger
  - Counterparty: Appili Therapeutics, Inc.
  - Effective: 2024-04-01
  source text: On April 1, 2024 (the “ Execution Date ”), Aditxt, Inc., a Delaware corporation (the “ Company ”), entered into an Arrangement Agreement (the “ Arrangement Agreement ”) with Adivir, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Adivir ” or the “ Buyer ”), and Appili Therapeutics, Inc., a Canadian corporation (“ Appili ”), pursuant to which, Adivir will acquire all of the issued and outstanding Class A common shares of Appili
  evidence_url: https://www.sec.gov/Archives/edgar/data/1726711/000121390024030466/0001213900-24-030466-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.